 was stricken
post-publication by the guidelines committee based on
further review of the evidence and is no longer valid (see
Supplementary Material on page 41S.e1, online only).
The vasoactive drug naftidrofuryl oxalate works by
enhancing aerobic glycolysis and oxygen consumption in
ischemic tissues, is commonly used in Europe, but is not
currently approved in the United States. It has been shown
to